Clinical Fellowships
Supports U.S. academic clinical fellowships training physicians in the multidisciplinary diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR Amyloidosis).
Funder: Alnylam Pharmaceuticals
Due Dates: August 28, 2026 (Clinical Fellowships submission deadline)
Funding Amounts: Up to $95,000 per institution for a one-year fellowship; funds for fellow salary and benefits only
Summary: Supports U.S. academic programs training physicians in the diagnosis, treatment, and research of Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) through multidisciplinary clinical fellowships.
Key Information: Awarded to institutions (not individuals); only ACGME-accredited U.S. programs with active cardiology fellowships are eligible.
Description
This opportunity provides institutional grants from Alnylam Pharmaceuticals to support educational clinical fellowship programs within U.S. academic healthcare organizations, specifically focused on Transthyretin-mediated Amyloidosis (ATTR Amyloidosis). The aim is to advance physician training in diagnosis, treatment, and research of ATTR Amyloidosis, fostering multidisciplinary collaboration to improve early recognition, treatment pathways, and the translation of emerging science into patient-centered care. Grants are intended exclusively for fellow salary and benefits, emphasizing comprehensive clinical and research experience, effective assessment methodologies, and robust mentorship infrastructure.
